glp 1 and bowel obstruction Acute Small Induced by Tirzepatide (Mounjaro) louisiana glp-1 gastrointestinal obstruction class

Pilot clinical studies and case reports describe nausea in 65% of subjects at doses above 0,5 mg (resolution 2-4 h post-injection), flushing in 55%, transient increases in blood pressure and tachycardia in 40-60% of subjects, with peak acute effects occurring 90-120 minutes post-dose

Referral triggers include persistent hyperglycemia despite therapy, suspected pancreatitis, acute kidney injury, gallbladder disease, or concerning cardiovascular symptoms

Since no sample was collected at the 2.5 h time point in our experiment, the different peaks may be due to different frequency of blood sampling

Whitney ER, Kemper TL, Bauman ML, Rosene DL, Blatt GJ